Service de Gastroentérologie, Département de Médecine, Université de Sherbrooke, 3001, 12e avenue nord, Sherbrooke, Québec, Canada.
Carcinogenesis. 2012 Mar;33(3):529-37. doi: 10.1093/carcin/bgr309. Epub 2011 Dec 26.
Recent evidences suggest that the activity of glycogen synthase kinase-3 (GSK3) contributes to the tumorigenic potential of pancreatic cancer cells through modulation of cell proliferation and survival. However, further investigations are needed to identify GSK3-dependent mechanisms involved in the control of pancreatic cancer cell proliferation and survival. This study was undertaken to provide further support for a role of GSK3 in pancreatic cancer cell growth as well as to identify new cellular and molecular mechanisms involved. Herein, we demonstrate that prolonged inhibition of GSK3 triggers an apoptotic response only in human pancreatic cancer cells but not in human non-transformed pancreatic epithelial cells. We show that prolonged inhibition of GSK3 activity increases Bim messenger RNA and protein expressions. Moreover, we provide evidence that activation of the c-jun N-terminal kinase (JNK) pathway is necessary for the GSK3 inhibition-mediated increase in Bim expression and apoptotic response. Finally, we demonstrate that concomitant inhibition of GSK3 potentiates the death ligand-induced apoptotic response in pancreatic cancer cells but not in non-transformed pancreatic epithelial cells and that this effect also requires JNK activity. Considering that different approaches leading to stimulation of death receptor signaling are under clinical trials for treatment of unresectable or metastatic pancreatic cancer, inhibition of GSK3 could represent an attractive new avenue to improve their effectiveness.
最近的证据表明,糖原合成酶激酶-3(GSK3)的活性通过调节细胞增殖和存活,有助于胰腺癌的致瘤潜能。然而,需要进一步的研究来确定与控制胰腺癌细胞增殖和存活有关的 GSK3 依赖性机制。本研究旨在进一步支持 GSK3 在胰腺癌细胞生长中的作用,并确定涉及的新的细胞和分子机制。在此,我们证明,GSK3 的长期抑制仅在人胰腺癌细胞中引发凋亡反应,而不在人非转化胰腺上皮细胞中引发。我们表明,GSK3 活性的长期抑制增加了 Bim 信使 RNA 和蛋白的表达。此外,我们提供的证据表明,c-jun N 端激酶(JNK)途径的激活对于 GSK3 抑制介导的 Bim 表达增加和凋亡反应是必需的。最后,我们证明,GSK3 的同时抑制增强了死亡配体诱导的胰腺癌细胞中的凋亡反应,但在非转化的胰腺上皮细胞中则没有,并且这种效应也需要 JNK 活性。考虑到不同的方法导致刺激死亡受体信号正在临床试验中用于治疗不可切除或转移性胰腺癌,抑制 GSK3 可能代表一种有吸引力的新途径,以提高其有效性。